Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker

BACKGROUND: Biomarkers to optimize extended adjuvant endocrine therapy for women with estrogen receptor (ER)–positive breast cancer are limited. The HOXB13/IL17BR (H/I) biomarker predicts recurrence risk in ER-positive, lymph node–negative breast cancer patients. H/I was evaluated in MA.17 trial for...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Sgroi, Dennis C., Carney, Erin, Zarrella, Elizabeth, Steffel, Lauren, Binns, Shemeica N., Finkelstein, Dianne M., Szymonifka, Jackie, Bhan, Atul K., Shepherd, Lois E., Zhang, Yi, Schnabel, Catherine A., Erlander, Mark G., Ingle, James N., Porter, Peggy, Muss, Hyman B., Pritchard, Katherine I., Tu, Dongsheng, Rimm, David L., Goss, Paul E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3888138/
https://ncbi.nlm.nih.gov/pubmed/23812955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djt146
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller